Evidence map›Paper›PMID 41078003›Full record

ArticleMolecular oncology2025

The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity.

Lena C M Krause, Rixa-Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lena C M KrauseMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.
Rixa-Mareike KöhnMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.
Christian IckesMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.
Julia LengerMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.
Jonas FischerMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.ORCID 0009-0008-5027-0005
Sabrina CappelloMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.
Ivan BogeskiMolecular Physiology, Institute for Cardiovascular Physiology, University Medical Centre, University of Göttingen, Germany.ORCID 0000-0001-9879-7174

Funding

Deutsche Forschungsgemeinschaft BO 3643/10-1Deutsche Forschungsgemeinschaft SFB1017Deutsche Forschungsgemeinschaft SFB1190Studienstiftung des Deutschen Volkes
6 · The paper itself

Abstract

Melanoma, the deadliest form of skin cancer, poses a significant challenge due to its genetic heterogeneity and high metastatic potential. While cytotoxic T cell (CTL)-based immunotherapies have made remarkable progress in recent years, the therapeutic potential of natural killer-(NK) cells is increasingly recognized. However, resistance mechanisms to both CTL- and NK-cell-mediated immunotherapies hinder effective treatment. To evaluate the exclusive role of NK-cells in anti-melanoma immunity, we performed 2D and 3D co-culture-based cytotoxicity assays under varying conditions. Our findings revealed a protective phenotype in melanoma cells following prolonged exposure to primary NK-cells. By combining experimental data with bioinformatic analyses, we identified key genes and pathways involved in melanoma cell adaptation to NK-cell-mediated killing (NKmK). We found that cytokines such as IFNγ play a major role in suppressing NKmK with MHC II surface expression being a critical factor. Targeting the master regulator CIITA, which governs MHC II expression and is affected by IFNγ, significantly reduced melanoma cell resistance to NKmK. This study provides potential strategies to overcome resistance to NK-cell-based immunotherapies and offers novel insights into melanoma immune escape mechanisms.

Indexed as

Cytotoxicity, ImmunologicHistocompatibility Antigens Class IIInterferon-gammaKiller Cells, NaturalMelanomaTrans-ActivatorsCell Line, TumorCoculture TechniquesHumansNuclear ProteinsHistocompatibility Antigens Class IIInterferon-gammaMHC class II transactivator proteinNuclear ProteinsTrans-ActivatorsIFNγimmunotherapymelanomaNK cells

Identifiers

PMID41078003
PMCPMC12591318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.